Nvidia Invests $35 Million into Biotech Technology Company

London-based Relation Therapeutics has raised $60 million - including $35 million from the venture arm of Nvidia – to advance their technology in generating, analyzing and interpreting human data about the behaviour of genes, cells and tissues to identify new therapeutic targets and translate those into transformational medicines.

This follows up on Nvidia’s $50 million investment in Recursion Pharmaceuticals in 2023, which focuses on advancing AI-assisted drug discovery models.

The following article originally appeared in Endpoints News.

The venture arm of Nvidia, the supercomputing giant rising up the world’s most valuable companies chart, is backing a computational drug discovery startup that’s headed toward the clinic for osteoporosis, a large field with few innovations.

Relation Therapeutics has added $35 million to its coffers, the company exclusively told Endpoints News. Nvidia’s NVentures, DCVC, Deerfield Management Company, Khosla Ventures, Abcam founder Jonathan Milner, ARK Invest and Magnetic Ventures contributed funds, which bring the total seed financing to $60 million.

For more, please find the original story source here.